China Healthcare Weekly (Aug.10)-Trump Plans Drug Tariff, Biosimilar VBP, BeiGene's Headwind in 25Q2

615 Views10 Aug 2025 09:26

Trump's threat of tariffs on drugs won't impact China innovative drug BD deals. Biosimilar VBP is expected to reshape market. BeiGene released strong Q2 results, but market cautious on future outlook

What is covered in the Full Insight:

Introduction
Impact of Trump's Drug Tariffs
Biosimilar VBP Developments
BeiGene's Quarterly Performance
Market Review and Risks

Xinyao (Criss) Wang

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 4-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream